Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab

Intern Med. 2021 Jan 1;60(1):145-150. doi: 10.2169/internalmedicine.4752-20. Epub 2020 Aug 22.

Abstract

Membranous nephropathy (MN) with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) is seen infrequently. Previous reports of patients with ANCA-GN with MN showed that the most frequent ANCA subtype was myeloperoxidase-ANCA. We herein present a 73-year-old woman with scleritis, hematuria, proteinuria, and positive serum proteinase 3 (PR3)-ANCA. She underwent a renal biopsy and was diagnosed with MN and ANCA-GN. Immunofluorescence staining for PR3 colocalized with IgG along the glomerular basement membrane were observed. Oral prednisolone and intravenous rituximab therapy immediately improved her symptoms and urinalysis abnormalities. PR3-ANCA may be involved in the pathogenesis of MN via the formation of immune complexes.

Keywords: glomerular disease; immune complex deposits; immunofluorescence staining; secondary membranous nephropathy; small vessel vasculitis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • Female
  • Glomerulonephritis*
  • Glomerulonephritis, Membranous* / complications
  • Glomerulonephritis, Membranous* / diagnosis
  • Glomerulonephritis, Membranous* / drug therapy
  • Humans
  • Myeloblastin
  • Peroxidase
  • Rituximab / therapeutic use

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Rituximab
  • Peroxidase
  • Myeloblastin